Clinical Trial

Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)

Name: Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC) — clinical trial record (NCT06086288)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PANDORA

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is an open label, multicenter, phase II study evaluating the activity and safety of pembrolizumab combined with cisplatin/carboplatin and etoposide as first line treatment in patients with advanced MCC.

Trial Details

NCT Number	NCT06086288
Lead Sponsor	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Conditions	Merkel Cell Carcinoma
Enrollment	35 participants
Start Date	2023-11
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2023-10-17